Bipartisan Support For Comparative Efficacy Policy Likely To Grow - McClellan
This article was originally published in The Pink Sheet Daily
Increasing interest in demonstrating safety, efficacy and value of medications will drive development of policies around comparative evidence, the former FDA head predicts.
You may also be interested in...
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.